Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients (ONTARGET-INDIA)
A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)
Descripción general del estudio
Estado
Condiciones
Descripción detallada
This is a multicentre, non-interventional, prospective, observational study which would be conducted in India to understand the usage and effect of saxagliptin as first add-on therapy after metformin. The study will enroll Type 2 Diabetes Mellitus (T2DM) patients who were inadequately controlled with metformin alone and have been recently (i.e. within past 15 days) prescribed saxagliptin as an add-on to metformin.
The Investigator/designee would get signed informed consent from potential subjects of the study. The patients who meet all inclusion and none of the exclusion criteria will be enrolled in the study. These patients will then be assigned a patient identification number for the study. The Investigator/designee will collect the information as per the study schedule. This will be considered as Visit 1 of the patients. The patients will be managed as per the routine clinical practice of the physician for their condition and this study will neither interfere/advise the Investigators/designee for any drug/medication to be prescribed to the patients nor prescribe any intervention to them.The enrolled patients would then be asked to visit their respective study sites after 3 months ( +7 days) for the Visit-2 of study.
Around 50 study centers throughout India will be selected with a goal of enrolling up to 1500 patients (approximately 30 subjects each per site). The study will be initiated after obtaining written approval of Independent/Institutional Ethics Committee and written Informed consent of the patient.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
new Delhi, India
- Research Site
-
-
Andhra Pradesh
-
Nellure, Andhra Pradesh, India
- Research Site
-
Vishakhapatnam, Andhra Pradesh, India
- Research Site
-
-
Assam
-
Guwahati, Assam, India
- Research Site
-
-
Delhi
-
New Delhi, Delhi, India
- Research Site
-
-
Gujarat
-
Ahmedabad, Gujarat, India
- Research Site
-
Rajkot, Gujarat, India
- Research Site
-
Vadodara, Gujarat, India
- Research Site
-
-
Haryana
-
Karnal, Haryana, India
- Research Site
-
Yamunanagar, Haryana, India
- Research Site
-
-
Karnataka
-
Bangalore, Karnataka, India
- Research Site
-
-
Kerala
-
Trivandrum, Kerala, India
- Research Site
-
-
Kochi
-
Cochin, Kochi, India
- Research Site
-
-
Madhya Pradesh
-
Bhopal, Madhya Pradesh, India
- Research Site
-
Indore, Madhya Pradesh, India
- Research Site
-
-
Maharashtra
-
Mumbai, Maharashtra, India
- Research Site
-
Pune, Maharashtra, India
- Research Site
-
-
Punjab
-
Amritsar, Punjab, India
- Research Site
-
Chandigarh, Punjab, India
- Research Site
-
Ludhiana, Punjab, India
- Research Site
-
-
Rajasthan
-
Jaipur, Rajasthan, India
- Research Site
-
Udaipur, Rajasthan, India
- Research Site
-
-
Tamiladu
-
Madurai, Tamiladu, India
- Research Site
-
-
Tamilnadu
-
Chennai, Tamilnadu, India
- Research Site
-
-
Telangana
-
Hyderabad, Telangana, India
- Research Site
-
Hyderebad, Telangana, India
- Research Site
-
-
Uttar Pradesh
-
Allahabad, Uttar Pradesh, India
- Research Site
-
Kanpur, Uttar Pradesh, India
- Research Site
-
Lucknow, Uttar Pradesh, India
- Research Site
-
Noida, Uttar Pradesh, India
- Research Site
-
-
West Bengal
-
Kolkata, West Bengal, India
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Patients willing to provide informed consent.
- Female or male patients aged 18 years or above.
- Patients with known case of Type 2 diabetes mellitus.
- Patients with inadequate glycaemic control taking metformin monotherapy (minimum dose of 500 mg OD) for at least 3 months.
- Patients who have recently (last 15 days) been prescribed saxagliptin in addition to metformin.
Exclusion Criteria:
- Patients with Type 1 diabetes mellitus.
- Patients taking glucose lowering drugs apart from metformin or saxagliptin.
- Any medical condition of the patient which in the opinion of Investigator would interfere with safe completion of the study.
- Pregnant or lactating women.
- Women of childbearing potential not ready to use an effective barrier contraceptive method during the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Medication usage in enrolled subjects
Periodo de tiempo: at 3 months
|
By Frequency of subjects taking different doses of saxagliptin and metformin
|
at 3 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Reduction in HbA1C
Periodo de tiempo: baseline and at 3 months
|
Compare the reduction in HbA1C levels from baseline to follow up visit with baseline HbA1C levels
|
baseline and at 3 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Silla de estudio: Dr Sanjay Kalra, MD, DM (Endocrinology), Bharti Research Institute of Diabetes & Endocrinology, Karnal
- Director de estudio: Dr Bhavesh P Kotak, FRCS, MS, D Orth, AstraZeneca Pharma India Ltd
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- D1680R00019
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .